玫瑰痤疮药物治疗研究进展

丽颖 郝(华北理工大学附属医院，中国)
欢欢 呼(华北理工大学附属医院，中国)
莹 郑(华北理工大学附属医院，中国)
洁 杨(华北理工大学附属医院，中国)

摘要

玫瑰痤疮是一种常见的慢性炎症性皮肤疾病，目前治疗方法有甲硝唑、肾上腺素能受体激动剂、伊维菌素、壬二酸、钙调磷酸酶抑制剂等外用药物治疗，抗生素类、异维 A 酸、羟氯喹、β 肾上腺素受体阻滞剂等系统药物治疗，本病进程可能数年甚至数十年的时间，且容易反复，故其治疗是一个复杂的过程。　

关键词

玫瑰痤疮；药物治疗；进展

参考

Id M S,Almeida L M C,Bewley A,et al. Recommendations for rosacea diagnosis,classification and management:update from the global ROSacea COnsensus 2019 panel[J].British Journal of Dermatology,2020(05):1090-1091.

Gether L , Overgaard L K , Egeberg A , et al. Incidence and prevalence of rosacea: a systematic review and meta-analysis[J]. British Journal of Dermatology,2018.

Li J , Wang B , Deng Y , et al. Epidemiological features of rosacea in Changsha, China: A population-based, cross-sectional study[J]. The Journal of Dermatology, 2020, 47.

WILKIN, J. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea*1, *2[J]. Journal of the American Academy of Dermatology, 2004(06):907-912.

Gallo R L , Granstein R D , Kang S , et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee[J]. Journal of the American Academy of Dermatology, 2017:148.

谢红付 , 李吉 . 中国玫瑰痤疮诊疗专家共识 (2016)[J]. 中华皮肤科杂志 ,2017(03):156-161.

Asai Y, Tan J, Baibergenova A, et al. Canadian Clinical Practice Guidelines for rosacea[J]. J Cutan Med Surg, 2016(05):432-445.

Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1guideline for the treatment of rosacea[J]. J Eur Acad Dermatol Venereol,

(11):1775-1791.

Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update:recommendations from the global ROSacea COnsensus （ROSCO）panel[J]. Br J Dermatol, 2017(02):465-471.

Sabrina, Narayanan, Andreas, et al. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system[J]. Journal of Pharmacy & Pharmacology, 2007.

Lev-Tov, Hadar A , Fisk, et al. Phytochemical and Botanical Therapies for Rosacea: A Systematic Review[J]. Phytotherapy research: PTR, 2015.

Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large commu-nity-based study of metronidazole gel in rosacea. Cutis. 2007;79(1): 73-80.

Wolf R , Orion E , Matz H . Co-existing sensitivity to metronidazole and isothiazolinone[J]. Clinical & Experimental Dermatology, 2010, 28.

Vincenzi C , Lucente P , Ricci C , et al. Facial contact dermatitis due to metronidazole[J]. Contact Dermatitis, 2010, 36.

European Medicines Agency. Assessment Report (EMEA/CHMP/115246/2014). London, UK: European Medicines Agency;2013. A vailable from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002642/WC500163196.pdf. Accessed April 16, 2014.

Mark J J , Melissa K , John M , et al. The role of brimonidine tartrate gel in the treatment of rosacea[J]. Clinical Cosmetic & Investigational Dermatology, 2015(08):529-538.

Piwnica D , Rosignoli C , de Ménonville, Séverine Thibaut, et al. Vasoconstriction and anti-inflammatory properties of the selective α adrenergic receptor agonist brimonidine[J]. Journal of Dermatological ence, 2014, 75(1):49-54.

Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study[J]. J Drugs Dermatol, 2014(01):56-61.

Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once daily topical brimonidine tartrate gel 0.5% for the treatment of moder-ate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol, 2013(06):650-656.

Fowler J, Jarratt M, Moore A, et al; Brimonidine Phase II Study Group. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two mul-ticentre, randomized and vehicle-controlled studies. Br J Dermatol, 2012(03):633-641.

Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol, 2014(01):56-61.

Jackson JM, Fowler J, Moore A, et al; Brimonidine Phase III Study Group. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. J Drugs Dermatol, 2014(06):699-704.

RhofadeTM (oxymetazoline hydrochloride) cream, for topical use: US prescribing information. https ://daily med.nlm.nih.gov/daily med/drugI nfo.cfm?setid =1ba1c c5b-4f7f-491b-a5af-a6a14 fb5affd. Accessed 12 Nov 2018.

Mckeage K , Lyseng-Williamson K A . Oxymetazoline 1% cream in erythema of rosacea: a profile of its use in the USA[J]. Drugs & Therapy Perspectives, 2019(01):7-12.

Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: Findings from the first REVEAL trial. J Drugs Dermatol, 2018(01):97-105.

Baumann L, Goldberg DJ, Stein-Gold L, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: Findings from the second REVEAL trial. J Drugs Dermatol, 2018(03):611-619.

Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial[J]. Journal of the American Academy of Dermatology, 2018.

M, Schaller, L. Dual anti-inflammatory and antiparasitic action of topical ivermectin 1% in papulopustular rosacea.[J]. Journal of the European Academy of Dermatology & Venereology Jeadv, 2017.

Martin Steinhoff, Marc Vocanson, Johannes J Voegel, 等 . Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments[J]. Advances in Therapy, 2016.

Husein Husein lAhmed, Steinhoff M . Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: A systematic review and meta analysis[J]. Dermatologic Therapy,2019(01):33.

Thibaut de Ménonville, Séverine, Rosignoli C , Soares E , et al. Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models[J]. Dermatology & Therapy, 2017.

Del Rosso JQ, Thiboutot D, Gallo R, Webster G, T anghetti E,Eichenfield LF , et al. Consensus recommendations from theAmerican Acne & Rosacea Society on the management of rosacea,part5:A guide on the management of rosacea. Cutis.2014;93:134- - -8.

Van Zuuren EJ, Fedorowicz Z, Carter B, vander Lin-den MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev.2015. CD003262. Available from:https://doi.org/10.1002/14651858.CD003262.pub5.

Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003(06):836-845.

Coda A B , Hata T , Miller J , et al. Cathelicidin, kallikrein 5, and serine protease activityis inhibited during treatment of rosacea with azelaic acid 15% gel.[J]. Journal of the American Academy of Dermatology, 2013(04):570-577.

Liu R H , Smith M K , Basta S A , et al. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials.[J]. Archives of Dermatology, 2006(08):1047-52.

凌诗琪 , 宗文凯 . 玫瑰痤疮的治疗进展 [J]. 中国麻风皮肤病杂志 ,2017(07):436-439.

Teraki Y, Hitomi K, Sato Y, Izaki S. Tacrolimus-induced rosacealike dermatitis: a clinical analysis of 16 cases associated with tacrolimus oint-ment application. Dermatology 2012(224): 309-314.

Fujiwara S, Okubo Y, Irisawa R, Tsuboi R. Rosaceiform dermatitis asso-ciated with topical tacrolimus treatment. J Am Acad Dermatol 2010; 62:1050-1052.

G, Garg, GP, et al. Clinical efficacy of tacrolimus in rosacea[J]. Journal of the European Academy of Dermatology & Venereology, 2009.

Ruzicka R, Assman T, Homey B. Tacrolimus: the drug for the millennium? Arch Dermatol, 1999(135): 574-580.

Meshkinpour A, Joannie S, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003(49): 145-147.

李雪莉 , 黄玉成 , 杨莉 . 他克莫司软膏治疗酒渣鼻临床疗效观察 [J].中国皮肤性病学杂志 ,2009(06):396-397.

Gül, ülker, G?nül, Müzeyyen, Kili? A , et al. A case of granulomatous rosacea successfully treated with pimecrolimus cream[J]. Journal of Dermatological Treatment, 2008(05):313-315.

Two AM，Wu W，Gallo RL，et a1．Rosacea：patr II.Topical and systemic therapies in the treatment of rosacea lJ J．J Am Acad Dermatol,2015(05):761-770.

Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol 2014;13: 685-688.

38. Sauder DN, Miller R, Gratton D, Danby W , Griffiths C, Phillips SB. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatolog Treat. 1997(02):79-85.

Jakhar D , Kaur I , Misri R . Topical 10% Tranexamic acid for erythematotelangiectatic steriod induced rosacea[J]. Journal of the American Academy of Dermatology, 2020.

Salleras M , Alegre M , Alonso-Usero V , et al. Spanish Consensus Document on the Treatment Algorithm for Rosacea[J]. 2019(07):533-

Baldwin HE. Oral therapy for rosacea. Journal of Drugs in Dermatology 2006(01):16-21.

Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003(04):234-45.

Rosso J Q D , Webster G F , Jackson M , et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.[J]. Journal of the American Academy of Dermatology, 2007(05):791-802.

M.M.D. van der Linden, A.R. van Ratingen, D.C. van Rappard,et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety[J]. British Journal of Dermatology, 2017.

19. Shidan E, Vicaut E, Chidiak H, Anselin E, Cribier B, Dréno B,et al. A randomized controlled trial of oral low dose isotretinoin For difficult to treat papulopustular rosacea. J Invest Dermatol.2016(136):1124- 9.

Uslu M,avk E, Karaman G, endur N. Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements. Acta Dermato-Venereologica 2012(01):73-75.

Uslu M,avk, E, Karaman G , et al. Rosacea Treatment with Intermediate-dose Isotretinoin: Follow-up with Erythema and Sebum Measurements[J]. Acta Derm Venereol, 2012(01):73-77.

潘廷猛 , 王鑫 , 陈雪路 , 等 . 羟氯喹联合红光治疗 60 例玫瑰痤疮临床观察 [J]. 临床皮肤科杂志 ,2019(05):300-304.

刘英姿 , 谢红付 , 李吉 , 等 . 羟氯喹治疗 60 例轻中度酒渣鼻的有效性及安全性临床观察 [J]. 临床皮肤科杂志 ,2015(04):254-257.

林达珊 , 江连枝 , 王雅丽 . 羟氯喹联合克拉霉素和医学保湿剂治疗玫瑰痤疮的疗效观察 [J]. 中国医疗美容 ,2018(09):26-29.

姜林娣 , 马莉莉 . 羟基氯喹引起的神经精神症状 3 例报道 [J]. 复旦学报：医学版 ,2008(05):792.

霍燕 , 张永锋 , 等 . 羟氯喹相关的色素沉着一例报道 J. 天津医学 ,2012(07):52.

Hsu CC,Lee JY.Carvedilol ofr the treatment of rerfactory facial fushing and persistent erythema of rosacea[J].Arch Dermatol,20l1(11):1258-1260.

DOI: http://dx.doi.org/10.26549/yzlcyxzz.v3i5.5285